These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 34194437)

  • 21. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.
    Lian X; Yang K; Li R; Li M; Zuo J; Zheng B; Wang W; Wang P; Zhou S
    Mol Cancer; 2022 Jan; 21(1):27. PubMed ID: 35062950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint Immunotherapy: Picking a Winner.
    Teng MW; Khanna R; Smyth MJ
    Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
    Sun J; Zheng Y; Mamun M; Li X; Chen X; Gao Y
    Biomed Pharmacother; 2020 Sep; 129():110504. PubMed ID: 32768978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
    Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
    Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in non-small cell lung cancer harbouring driver mutations.
    Addeo A; Passaro A; Malapelle U; Banna GL; Subbiah V; Friedlaender A
    Cancer Treat Rev; 2021 May; 96():102179. PubMed ID: 33798954
    [No Abstract]   [Full Text] [Related]  

  • 31. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
    Zhang S; Bai X; Shan F
    Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
    Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage targeting in cancer.
    Lopez-Yrigoyen M; Cassetta L; Pollard JW
    Ann N Y Acad Sci; 2021 Sep; 1499(1):18-41. PubMed ID: 32445205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research.
    Zhang Y; Mou GZ; Li TZ; Xu WT; Zhang T; Xue H; Zuo WB; Li YN; Luo YH; Jin CH
    Technol Cancer Res Treat; 2021; 20():15330338211004942. PubMed ID: 33759637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Hude I; Sasse S; Engert A; Bröckelmann PJ
    Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.